Clinical trial
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell…
NCT00113529 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00113529 |
|---|---|
| Title | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma |
| Official title | A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Gefitinib + Sunitinib |
| Enrollment | 42 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Jun 9, 2005 |
| Last update posted | Aug 29, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: